FDA provides information on COVID-19 breath test, prenatal screening tests

Last week, the Food and Drug Administration (FDA) granted emergency use authorization for the first breathalyzer test designed to detect COVID-19 in adults. The test, given under the supervision of a health care provider, can detect the virus in breath samples in under three minutes. The FDA provided additional information in a fact sheet. On April 19, the agency warned against misinterpreting the results of noninvasive prenatal screening tests. The FDA said the tests are not intended to diagnose genetic abnormalities, and none have received FDA authorization. The agency also announced it is considering revising its opioid disposal requirements and is seeking comment on its draft mail-back plan.